## Alvina A Acquaye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7024264/publications.pdf

Version: 2024-02-01

25 309 7 16
papers citations h-index g-index

26 26 26 551 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments. Neuro-Oncology Practice, 2022, 9, 429-440.	1.6	3
2	Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients. Neuro-Oncology Practice, 2022, 9, 526-535.	1.6	4
3	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
4	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. Neuro-Oncology Practice, 2021, 8, 460-474.	1.6	12
5	Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. Neuro-Oncology Practice, 2020, 7, 38-51.	1.6	9
6	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. Journal of Neuro-Oncology, 2020, 149, 161-170.	2.9	3
7	The prevalence of altered body image in patients with primary brain tumors: an understudied population. Journal of Neuro-Oncology, 2020, 147, 397-404.	2.9	6
8	HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS. Neuro-Oncology, 2019, 21, vi111-vi112.	1.2	0
9	The lomustine crisis: awareness and impact of the 1500% price hike. Neuro-Oncology, 2019, 21, 1-3.	1.2	76
10	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. Journal of Patient-Reported Outcomes, 2019, 3, 58.	1.9	2
11	QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENT'S EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS). Neuro-Oncology, 2018, 20, vi217-vi218.	1.2	0
12	HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS). Neuro-Oncology, 2018, 20, vi115-vi115.	1.2	0
13	INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK. Neuro-Oncology, 2018, 20, vi145-vi146.	1.2	0
14	QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi215-vi215.	1.2	1
15	HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT. Neuro-Oncology, 2018, 20, vil13-vil13.	1.2	0
16	QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi216-vi216.	1.2	0
17	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. Neuro-Oncology, 2018, 20, vi164-vi164.	1.2	2
18	PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP). Neuro-Oncology, 2018, 20, vi170-vi170.	1.2	1

#	Article	IF	CITATIONS
19	QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	0
20	QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS). Neuro-Oncology, 2018, 20, vi217-vi217.	1.2	0
21	Hope and mood changes throughout the primary brain tumor illness trajectory. Neuro-Oncology, 2016, 18, 119-125.	1.2	20
22	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro-Oncology, 2016, 18, 252-260.	1.2	105
23	The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire–Chronic. Neuro-Oncology, 2015, 17, 1114-1120.	1.2	22
24	The impact of symptom interference using the MD Anderson Symptom Inventoryâ€Brain Tumor Module (MDASIâ€BT) on prediction of recurrence in primary brain tumor patients. Cancer, 2011, 117, 3222-3228.	4.1	35
25	Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests. Neuro-Oncology Practice, 0, , .	1.6	3